

03-28-02

0300

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

MAR 27 2002

(to be used for all correspondence after initial filing)

Application Number 09/788,308

Filing Date 02/16/2001

First Named Inventor Barron

Group Art Unit 1646

Examiner Name

Total Number of Pages in This Submission

3

Attorney Docket Number

6374

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Response☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☐ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/ Incomplete Application☐ Response to Missing Parts under 37 CFR 1.52 or 1.53☐ Assignment Papers (for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a Provisional Application☐ Power of Attorney, Revocation Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s)☐ After Allowance Communication to Group☐ Appeal Communication to Board of Appeals and Interferences☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please identify below):

Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure Statement Regarding Substitute Sequence Listing CD-R containing Sequence Listing

Remarks

Applicant believes this response is timely submitted. If, however, an extension of time is required, please consider this paper a petition therefore, and authorization is hereby granted to charge any deficient fees required to Deposit Account No. 18-0882.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or individual name

Rodney D. DeKruif
Reinhart Boerner Van Deuren s.c.

Signature

Date

03/27/2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EL803231036US in an envelope addressed to: Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 S. Clark Place, Arlington, VA 22202 on March 27, 2002.

Typed or printed name

Rodney D. DeKruif, Esq.

Signature

Date

03/27/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. MW 843065

MW/836751


PATENT

I hereby certify that this paper or fee is being deposited with United States Postal Service as Express Mail No. EL803231036US in an envelope addressed to: Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 S. Clark Place, Arlington, VA 22202, on March 27, 2002.

Reinhart Boerner Van Deuren s.c.

Dated: March 27, 2002

BY:


Rodney D. DeKruif

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Barron, et al.

Serial No: 09/788,308

Filed: 02/16/2001

For: POLYPEPTOID
PULMONARY
SURFACTANTS

)

)

)

)

)

)

)

Attorney Docket No.: 6374

Box Sequence
Commissioner for Patents
Washington, D.C. 20231

Statement Regarding Substitute Sequence Listing

Dear Sir:

Applicants hereby confirm that the content of the substitute amino acid sequence listing information provided herewith does not include new matter and does not go beyond the original disclosure in the application, as filed; and further state that the substitute sequence listing information recorded and provided in computer readable form is identical to the originally filed (10/22/01) written sequence listing.


The Examiner is invited to contact the undersigned if it is believed that additional sequences should be listed, or if there remains any other issue relating to the present submission and statement.

Respectfully submitted,



Rodney D. DeKruif
Attorney for Applicant
Registration No. 35,853

Reinhart Boerner Van Deuren s.c.
1000 North Water Street
Suite 2100
Milwaukee, WI 53202
Telephone: 414/298-8360



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/788,308	02/16/2001	Annelise E. Barron	6374

22922

REINHART BOERNER VAN DEUREN S.C.
ATTN: LINDA GABRIEL, DOCKET COORDINATOR
1000 NORTH WATER STREET
SUITE 2100
MILWAUKEE, WI 53202

CONFIRMATION NO. 7049

FORMALITIES LETTER



OC000000007379702

Date Mailed: 01/28/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE